Ann Dermatol.
2020 Jun;32(3):255-257. 10.5021/ad.2020.32.3.255.
Secukinumab Response in Korean Patients with Moderate to Severe Plaque-Type Psoriasis Irrespective of Previous Biologic Use: 1-Year Experience at a Single Center
- Affiliations
-
- 1Department of Dermatology, Ajou University School of Medicine, Suwon, Korea
- KMID: 2500766
- DOI: http://doi.org/10.5021/ad.2020.32.3.255
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Nummular Eczema-Like Eruption after Secukinumab Treatment
- Efficacy and Safety of Secukinumab for the Treatment of Moderate to Severe Psoriasis in Korea
- Safety of Adalimumab, Ustekinumab, Secukinumab, Guselkumab in Korean Patients with Moderate to Severe Psoriasis: A Real-World Data in a Single Medical Center
- Comparison of Short- and Long-Term Efficacy between Interleukin-17A and Interleukin-23 Inhibitors among Patients with Moderate-to-Severe Plaque Psoriasis: A Single Center Experience
- A Case of Plaque-type Infantile Psoriasis on Both Flank
